Nurix therapeutics announces initial data from the first phase 1a dose escalation trial of nx-2127 in patients with relapsed or refractory b cell malignancies

Robust btk target degradation achieved in all patients treated to date
NRIX Ratings Summary
NRIX Quant Ranking